首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1738571

2026-2032 年乾眼症治療市場（依產品類型、通路和地區）

Dry Eye Syndrome Treatment Market By Product Type (Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Region for 2026-2032

出版日期: 2025年05月12日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

乾眼症治療市場評估 - 2026-2032

乾眼症的盛行率不斷上升，尤其是人口老化和螢幕使用者數量的增加，正在推動乾眼症治療市場的發展。根據 Verified Market Research 分析師預測，乾眼症治療市場規模將從 2024 年的約 88.1 億美元下降到 2032 年的 227.1 億美元。

乾眼症治療市場的快速擴張主要歸因於全球對有效治療方法的需求不斷增加以及治療方案的技術進步，預計這將推動市場在 2026 年至 2032 年期間以 13.86% 的複合年成長率成長。

乾眼症治療市場定義/概述

乾眼症是一種以淚液分泌不足和淚液蒸發過快為特徵的疾病，會導致不適和視力下降。乾眼症的治療方法包括人工淚液、抗發炎藥物以及保留或刺激淚液分泌的手術。

此外，乾眼症的治療有廣泛的應用，包括即時緩解症狀、控制潛在原因和預防進一步的併發症。無防腐劑配方和新藥物輸送系統等治療方法的改進正在改善患者的治療效果，從而推動市場成長。

推動乾眼症治療市場成長的關鍵因素有哪些？

乾眼症症狀日益普遍，推動了市場發展。根據美國美國超過 1,600 萬成年人被診斷出患有乾眼症，另有數百萬人可能尚未確診。患者數量的成長催生了對更有效治療方案的需求。

人口老化正在催生巨大的乾眼症治療需求。根據世界衛生組織 (WHO) 的數據，到 2030 年，全球六分之一的人口將超過 60 歲。由於乾眼症在老年人群中更為普遍，人口老化預計將成為市場擴張的驅動力。

此外，螢幕使用時間的增加和數位眼睛疲勞也推動了對乾眼症治療的需求。根據視力委員會2020年發布的一項調查，59%的美國人因長時間使用螢幕而出現數位眼睛疲勞症狀，這與乾眼症直接相關。隨著螢幕使用時間的增加，對有效治療方法的需求也在成長。

影響乾眼症治療市場採用的主要挑戰有哪些？

乾眼症創新療法的高昂成本是其廣受接受的一大障礙。長期治療需要昂貴的處方藥、專業眼藥水以及諸如淚小管塞和熱脈衝系統等醫療設備。在醫療保險覆蓋有限或自付費用較高的地區，患者面臨巨大的治療障礙，這導致他們推遲治療或使用對控制病情無益的非處方藥。

許多出現症狀的人沒有就醫，因為他們誤以為這只是暫時的不適或環境因素。此外，醫療保健提供者並不總是將乾眼症視為重大健康問題，尤其是在早期階段。缺乏認知和診斷阻礙了有效治療的實施，因為患者不知道這種疾病是慢性的，也不知道有專門的治療方法可以顯著改善他們的生活品質。

此外，治療結果的差異也對乾眼症治療方法的採用構成了挑戰。由於乾眼症的成因多種多樣，包括環境因素、荷爾蒙變化和潛在疾病，因此不同患者的治療結果差異很大。有些患者對某些治療方法沒有反應，而有些患者則會出現副作用，導致不願意繼續使用。這種治療結果的不可預測性導致患者感到沮喪，降低了對聯合治療方法的依從性，並降低了旨在長期控制乾眼症的先進治療方法的整體採用率。

The increasing prevalence of dry eye syndrome, particularly among the aging population and increased screen time users, is driving the Dry Eye Syndrome Treatment Market upwards. According to the analyst from Verified Market Research, the Dry Eye Syndrome Treatment Market is estimated to reach a valuation of USD 22.71 Billion in 2032, by subjugating around USD 8.81 Billion valued in 2024.

The rapid expansion of the Dry Eye Syndrome Treatment Market is primarily driven by the rising global demand for effective therapies, as well as technological advancements in treatment options. It enables the market to grow at a CAGR of 13.86% from 2026 to 2032.

Dry Eye Syndrome Treatment Market: Definition/ Overview

Dry eye syndrome is a condition characterized by insufficient tear production or rapid tear evaporation, leading to discomfort and potential vision problems. Treatment options for dry eye syndrome include artificial tears, anti-inflammatory medications, and procedures to conserve tears or stimulate tear production.

Furthermore, dry eye syndrome treatments have a wide range of applications, including providing immediate relief from symptoms, managing underlying causes, and preventing further complications. Improved treatments, such as preservative-free formulations and novel drug delivery systems, are enhancing patient outcomes and driving market growth.

What are the Key Drivers Propelling the Growth of the Dry Eye Syndrome Treatment Market?

Dry eye condition is becoming increasingly common, which is a major market driver. According to the National Eye Institute (NEI), more than 16 million adults in the United States have been diagnosed with DES, with millions more potentially undiagnosed. The growing patient population demands more effective treatment choices.

The aging population is greatly increasing the need for dry eye remedies. According to the World Health Organization (WHO, by 2030, one in every six persons worldwide would be 60 or older. Because dry eye conditions are more common among older persons, the aging population is likely to drive market expansion.

Furthermore, the increase in screen time and digital eye strain is driving demand for dry eye remedies. According to a Vision Council study published in 2020, 59% of American people express symptoms of digital eye strain because of prolonged screen use, which is directly linked to dry eye syndrome. As screen time increases, so does the demand for effective therapies.

What are the Key Challenges Impacting the Adoption of Dry Eye Syndrome Treatment in the Market?

The high expense of innovative treatments for dry eye syndrome is a major barrier to their acceptance. Long-term treatment requires expensive prescription medications, specialist eye drops, and medical devices such as punctual plugs or thermal pulsation systems. Patients in areas with limited healthcare coverage or high out-of-pocket charges face considerable barriers due to these prices. Patients delay therapy or use over-the-counter medicines, which are not beneficial for managing the illness.

Many individuals experiencing symptoms do not seek medical attention, mistaking their condition for temporary discomfort or attributing it to environmental factors. Furthermore, healthcare providers do not always prioritize dry eye syndrome as a significant health issue, especially in the early stages. This lack of awareness and diagnosis hinders the adoption of effective treatments, as patients do not realize the chronic nature of the condition or the availability of specialized therapies that could significantly improve their quality of life.

Furthermore, the variability in treatment effectiveness also poses a challenge in the adoption of dry eye syndrome treatments. Since dry eye syndrome has multiple causes, including environmental factors, hormonal changes, and underlying medical conditions, treatment outcomes vary greatly from one patient to another. Some patients do not respond well to certain therapies or experience side effects that discourage continued use. This unpredictability in treatment response led to patient frustration, reduced compliance with prescribed therapies, and lower overall adoption of advanced treatments designed to manage the condition long-term.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for Artificial Tears?

According to VMR analysis, the artificial tears segment is estimated to dominate the market in the product type segment during the forecast period. Artificial tears provide immediate relief by lubricating the eyes and are widely available over the counter, making them highly accessible to patients. This widespread availability and ease of use contribute significantly to their market dominance.

Also, technological advancements have led to the development of preservative-free and long-lasting formulations of artificial tears. These innovations have enhanced the efficacy and safety profile of artificial tears, making them more appealing to both patients and healthcare providers. The improved formulations address concerns about preservative-related irritation and offer longer-lasting relief, further driving their popularity in the market.

Furthermore, artificial tears are often recommended as a first-line treatment for dry eye syndrome by eye care professionals. They are suitable for mild to moderate cases of dry eye and be used in conjunction with other treatments for more severe cases. This application's versatility contributes to their widespread use and market dominance.

What are the Potential Factors for the Growth of Retail Pharmacies in the Market?

The retail pharmacies segment is estimated to dominate the Dry Eye Syndrome Treatment Market during the forecast period. Retail pharmacies offer widespread accessibility and convenience for patients seeking over-the-counter dry eye treatments like artificial tears and lubricating eye drops. They are often the first point of contact for individuals looking for immediate relief from dry eye symptoms, contributing to their market dominance.

The growing number of chain pharmacies and drugstores has significantly expanded the reach of retail pharmacies. These establishments often offer a wide range of dry eye products, from basic artificial tears to more specialized treatments. The convenience of accessing these products alongside other healthcare needs makes retail pharmacies a preferred channel for many consumers.

Furthermore, many retail pharmacies now offer personalized in-store consultations with pharmacists. These consultations provide valuable guidance to customers in selecting appropriate dry eye treatments, enhancing the overall customer experience, and building trust. This personalized approach, combined with the immediate availability of products, strengthens the position of retail pharmacies in the Dry Eye Syndrome Treatment Market.

Country/Region-wise Acumens

What are the Key Factors that Contribute to North America's Edge in the Market?

According to VMR Analyst, North America is estimated to dominate the Dry Eye Syndrome Treatment Market during the forecast period. North America, particularly the U.S., has a high prevalence of dry eye syndrome, driving the demand for treatment options. According to the American Academy of Ophthalmology, approximately 16 million people in the U.S. have been diagnosed with dry eye disease. This large patient population supports the region's dominance in the market for dry eye treatments.

North America benefits from strong research and development activities in the healthcare sector. This leads to innovative product launches and advanced treatment options for dry eye syndrome. The region's robust healthcare infrastructure and high awareness of eye health among the population further cement its market dominance.

Furthermore, the increasing use of digital devices and screen time, particularly in the U.S., has contributed to a rising number of dry eye cases. A report from the Vision Council revealed that nearly 80% of American adults use digital devices for more than two hours per day, which significantly increases the risk of developing dry eye. This growing trend is fueling the demand for effective treatments in North America.

How Do Demographic Shifts Shape the Market Landscape in the Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth rate within the Dry Eye Syndrome Treatment Market during the forecast period. The rapid urbanization and increasing pollution levels in Asia-Pacific are contributing to the rising prevalence of dry eye syndrome. A study published by the World Health Organization (WHO) highlighted that many major cities in Asia, such as New Delhi and Beijing, experience high levels of air pollution, which exacerbates eye health issues, including dry eye.

The aging population across many countries in the Asia-Pacific region is another significant driver for the Dry Eye Syndrome Treatment Market. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the number of people aged 60 or older in Asia-Pacific is expected to increase from 630 million in 2020 to 1.3 billion by 2050. As dry eye syndrome is more prevalent among older adults, this demographic shift is contributing to the growing demand for treatment solutions.

Furthermore, the rapid adoption of digital devices, particularly in countries like China, Japan, and India, is fueling the rise in dry eye syndrome cases. According to a report by the Indian Council of Medical Research (ICMR), more than 50% of Indian adults experience digital eye strain due to excessive screen time, leading to a higher prevalence of dry eye symptoms. This growing trend of digital device usage is significantly boosting the demand for dry eye treatments in the Asia-Pacific region.

Competitive Landscape

The Dry Eye Syndrome Treatment Market's competitive landscape is characterized by a diverse range of companies, including pharmaceutical giants, specialty eye care companies, and innovative startups, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the Dry Eye Syndrome Treatment Market include:

Novartis AG, Allergan plc, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Akorn, Inc., Thea Pharmaceuticals Limited, OASIS Medical.

Latest Developments

In May 2023, Bausch + Lomb acquired Blink Tears from Johnson & Johnson Vision. This acquisition strengthens Bausch + Lomb's over-the-counter eye care product portfolio, expanding its market reach in the dry eye treatment space.

In October 2022, Novartis received FDA approval for its Xiidra (lifitegrast ophthalmic solution) for the treatment of dry eye disease in patients 17 years and older. The approval enhances the company's stronghold in the growing dry eye market by offering a proven therapeutic solution.

1 INTRODUCTION OF GLOBAL DRY EYE SYNDROME TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DRY EYE SYNDROME TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Artificial Tears
5.3 Anti-inflammatory Drugs
5.4 Punctal Plugs
5.5 Secretagogues
5.6 Others

6 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
6.2 Hospital Pharmacies
6.3 Retail Pharmacies
6.4 Online Pharmacies

7 GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL DRY EYE SYNDROME TREATMENT MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Novartis AG
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Allergan plc
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Bausch Health Companies Inc.
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Santen Pharmaceutical Co., Ltd.
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Johnson & Johnson
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Otsuka Pharmaceutical Co., Ltd.
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Sun Pharmaceutical Industries Ltd.
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Akorn, Inc.
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Thea Pharmaceuticals Limited
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 OASIS Medical
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments